Risk scoring improved clinical decisions and outcomes in high-risk patients with early-stage diabetic kidney disease


New, real-world evidence demonstrating that the KidneyIntelX bioprognostic test resulted in changed clinical decision making for patients in the early stage of diabetic kidney disease (DKD) being cared for within the Mount Sinai Health System’s Population Health Ambulatory Pharmacy and Condition Management programs has been published in the Journal of Primary Care & Community Health. The majority of patients were being treated by their primary care physician.

World Cup protesters are using AR Snap filters to display the pride flag

Previous article

How neurons autonomously regulate their excitability

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations